Adeza Biomedical Corporation Announces Exercise of Underwriters' Over-Allotment Option.

SUNNYVALE, Calif. -- Adeza Biomedical Corporation (NASDAQ:ADZA) today announced that the underwriters of its recent initial public offering of 3,750,000 shares of its common stock have exercised in full their over-allotment option to purchase an additional 562,500 shares of common stock from Adeza at the initial public offering price of $16.00 per share, less an underwriting discount of $1.12 per share.

The proceeds to Adeza, after deducting underwriting discounts, from the exercise of the over-allotment option are approximately $8.4 million, increasing the total net proceeds from the equity offering to approximately $62.4 million, after deducting underwriting discounts and estimated offering expenses.

UBS Securities LLC acted as the sole book-running manager of the offering, and SG Cowen & Co., Thomas Weisel Partners LLC and William Blair & Company acted as co-managers.

This press release does not constitute an offer to sell or the solicitation to buy any of the aforementioned securities. The offering of these securities may be made only be means of a prospectus. Copies of the prospectus may be obtained from UBS Securities LLC, Attention: Prospectus Dept., 299 Park Avenue, New York, NY 10171.

Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare, using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, the Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for broad use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility.